National Healthcare Group and Trendlines Enter into MOU

To establish partnership and co-develop innovative healthcare solutions

Singapore, 16 November 2017– Trendlines Medical Singapore Pte Ltd ("**Trendlines Singapore**"), a subsidiary of The Trendlines Group Ltd ("**Trendlines**") (SGX: 42T; OTCQX: TRNLY), a company focused on developing innovation-based medical and agricultural companies and National Healthcare Group Pte Ltd ("**NHG**"), a company incorporated under the Ministry of Health, Singapore and a leader in public healthcare in Singapore, recognised at home and abroad for the quality of its medical expertise and facilities, medical education and research, jointly announced today that Trendlines Singapore and NHG have entered into a Memorandum of Understanding (**MOU**), establishing a partnership between NHG and Trendlines Singapore to collaborate in identifying clinical unmet needs and developing innovative technological solutions to address these needs for local and global clinical demands.

The MOU will leverage the clinical expertise of NHG clinicians and healthcare professionals, as well as the innovation and technological expertise of Trendlines and its affiliated companies. Under the MOU, NHG will identify key problem statements and unmet clinical needs, while Trendlines Singapore and its affiliated companies will develop innovative solutions to address these needs. NHG and Trendlines will collaborate closely and jointly refine the development through clinical validation of solutions within the clinical infrastructure of NHG. Beyond the MOU, it is envisaged that start-up companies may be established in Singapore and incubated by Trendlines Singapore to develop the solutions into commercial products for the global market.

Commenting on the MOU, Mr Todd Dollinger, Chairman of Trendlines Singapore and CEO and Chairman of The Trendlines Group Ltd, said, **"**We are very pleased to establish this collaboration with NHG. At Trendlines, we are constantly seeking to invent and develop concepts to improve the human condition – whether through medical innovation or agricultural technology. When we established Trendlines Singapore in February of this year, we extended our vision to capitalise on the strong healthcare infrastructure in Singapore. Today's collaboration with NHG bears further testament to our resolve to seek innovative technological solutions to address clinical needs. We are confident that combining our expertise with the strong clinical standing of the hospitals and physicians of NHG, we will see successful companies and medical solutions developed, not just to address the local market, but also the global landscape facing similar medical concerns."

Adjunct Professor Lim Tock Han, Deputy Group CEO (Education & Research) of NHG, said, “Good population health – comprising physical, social and mental well-being – is a shared responsibility that must be owned by all sectors, not just public healthcare. NHG believes in forging collaborations with partners such as Trendlines to develop innovative solutions to deliver better care for our population, to empower people to better manage their health and to encourage them to adopt healthier lifestyles.”

Associate Professor Thomas Lew, Chairman Medical Board at Tan Tock Seng Hospital and Director, Centre for Medical Technologies and Innovations, NHG, added, “The Centre for Medical Technologies and Innovation **(CMTi)** was established to promote the culture of innovation in all our institutions, and to translate innovative ideas into practical working solutions and products. Through CMTi, NHG is privileged to partner with Trendlines Singapore through our MOU to foster closer collaboration in co-developing clinical, needs-driven healthcare-related technological solutions. Suitable joint projects will be identified based on emergent and important clinical needs from practising NHG clinicians; this is coupled with engineering and technological expertise from Trendlines, and together, we can establish collaborative projects that will be meaningful and beneficial to the population we serve.”

NHG and Trendlines Singapore have already identified three potential areas of collaboration, namely, to develop innovations to improve the condition of inpatients with fragile skin; to develop more efficient ways to monitor vital signs; and to find more effective solutions to ensure the safe delivery of nutrition to patients.

Mr Eric Loh, CEO of Trendlines Singapore commented, “We provide business and technology incubation to our portfolio companies in order for them to develop excellent medical products that address unmet clinical needs. We have identified investment opportunities and have begun our investment plans in Singapore. This collaboration with NHG will enable us to expand our scope of technology development and it gives our companies the opportunity to receive good clinical validation and potential product adoption. We are confident that this first collaboration with healthcare institutions here will add value to the healthcare ecosystem and create accretive success to the medical technology start-up environment in Singapore.”

- The End -

About Trendlines Medical Singapore Pte Ltd
Trendlines Medical Singapore is a medical technology start-up incubator established by Trendlines and B. Braun, one of the world's leading medical device companies. Trendlines Medical Singapore discovers, invests in, incubates, and provides broad-ranging support to nurture and develop our Singapore-based novel medical device and companies with a view toward success in the global market.

About The Trendlines Group Ltd
Trendlines is an innovation commercialisation company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfil its mission to improve the human condition. An intensely hands-on investor, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

About National Healthcare Group
The National Healthcare Group (NHG) is a leader in public healthcare in Singapore, recognised at home and abroad for the quality of its medical expertise and facilities. Care is provided through an integrated network of six primary care polyclinics, acute care and tertiary hospitals, national specialty centres and business divisions. Together they bring a rich legacy of medical expertise to our philosophy of integrated patient-centred care.

NHG's vision is "Adding Years of Healthy Life". This vision goes beyond merely healing the sick to the more difficult and infinitely more rewarding task of preventing illness and preserving health and quality of life. With some 18,000 staff, NHG aims to provide care that is patient-centric, accessible, seamless, comprehensive, appropriate and cost-effective. As the Regional Health System (RHS) for Central Singapore, it is vital for NHG to partner and collaborate with stakeholders, community advisors, and voluntary welfare organisations. Together with our patients, their families and caregivers, we aim to deliver integrated healthcare services and programmes that help in Adding Years of Healthy Life to all concerned. More information is available at www.nhg.com.sg.

Investor Contact Information
Israel
Judith Kleinman, Director Investor Relations & Corporate Communications
judith@trendlines.com
Tel: +972.72.260.7000

Singapore
Reyna MEI, Financial PR
reyna@financialpr.com.sg
Tel: +65.6438.2990

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte Ltd (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).